Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Summary

In adults who had already achieved weight loss with injectable incretin therapy, once-daily oral orforglipron maintained a significantly larger fraction of prior weight reduction than placebo over 52 weeks in two independent cohorts. Key secondary endpoints were met and adverse events were primarily mild-to-moderate gastrointestinal effects.

Key Findings

• In cohort 1 (prior tirzepatide), orforglipron maintained 74.7% of prior weight loss vs 49.2% with placebo at week 52 (MBE difference 25.5%, P<0.001).
• In cohort 2 (prior semaglutide), orforglipron maintained 79.3% vs 37.6% with placebo at week 52 (MBE difference 41.7%, P<0.001).
• All key secondary endpoints were met; gastrointestinal adverse events were the most common and were mostly mild-to-moderate.

Clinical Implications

For patients transitioning off injectable GLP-1–based therapies, orforglipron offers an oral maintenance option to preserve most of the achieved weight loss, with manageable GI tolerability.

Limitations

• No active comparator arm continuing injectable obesity medications
• Maintenance period limited to 52 weeks; long-term durability beyond 1 year is unknown

Future Directions

Head-to-head comparisons with continued injectable therapy and longer follow-up are needed to define optimal maintenance sequencing and durability.